Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
3 Min
More GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus®…
- Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments
- Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4, 2020